Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16. https://doi.org/10.1001/jama.2017.7112.

CAS  Article  PubMed  Google Scholar 

Harbeck N, Penault-Llorca F, Cortes J, et al. Breast Cancer. 2019;5. https://doi.org/10.1038/s41572-019-0111-2.

Guidelines NCCN. Breast Cancer (Version 1.2021). Published 2021. Accessed 2 Mar 2021. https://www.nccn.org/professionals/physician_gls/default.aspx#site

Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021. JNCCN J Natl Compr Cancer Netw. 2021;19(1):77–102. https://doi.org/10.6004/JNCCN.2021.0001.

CAS  Article  Google Scholar 

Metcalfe K, Eisen A, Senter L, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121(1):15–21. https://doi.org/10.1038/s41416-019-0446-1.

Article  PubMed  PubMed Central  Google Scholar 

Hartmann LC, Thomas A, Schaid DJ, et al. Efficacy of bilateral. Cancer. 2001;93(21):1633–7.

CAS  Google Scholar 

Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22(6):1055–62. https://doi.org/10.1200/JCO.2004.04.188.

Article  PubMed  Google Scholar 

Liede A, Mansfield CA, Metcalfe KA, et al. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat. 2017;165(2):433–44. https://doi.org/10.1007/s10549-017-4332-3.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Easton DF, Narod SA, Ford D, Steel M. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. Lancet (London, England). 1994;344(8924):761. https://doi.org/10.1016/s0140-6736(94)92256-x.

CAS  Article  Google Scholar 

Tonin P, Serova O, Simard J, Lenoir G, Feunteun J, Morgan K, et al. The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. Hum Mol Genet. 1994;3(9):1679–82. https://doi.org/10.1093/hmg/3.9.1679.

CAS  Article  PubMed  Google Scholar 

Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM. RANKL/RANK-beyond bones. J Mol Med (Berl). 2011;89(7):647–56. https://doi.org/10.1007/s00109-011-0749-z.

CAS  Article  Google Scholar 

Nagy V, Penninger JM. The RANKL-RANK Story. Gerontology. 2015;61(6):534–42. https://doi.org/10.1159/000371845.

CAS  Article  PubMed  Google Scholar 

Kotsopoulos J. BRCA mutations and breast cancer prevention. Cancers (Basel). 2018;10(12):1–15. https://doi.org/10.3390/cancers10120524.

CAS  Article  Google Scholar 

Kiesel L, Kohl A. Role of the RANK/RANKL pathway in breast cancer. Maturitas. 2016;86:10–6. https://doi.org/10.1016/j.maturitas.2016.01.001.

CAS  Article  PubMed  Google Scholar 

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19. https://doi.org/10.1016/S0092-8674(00)80209-3.

CAS  Article  PubMed  Google Scholar 

Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol. 2014;5(OCT):1–11. https://doi.org/10.3389/fimmu.2014.00511.

CAS  Article  Google Scholar 

Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103(1):41–50. https://doi.org/10.1016/s0092-8674(00)00103-3.

CAS  Article  PubMed  Google Scholar 

Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103–7. https://doi.org/10.1038/nature09495.

CAS  Article  PubMed  Google Scholar 

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98–102. https://doi.org/10.1038/nature09387.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Joshi PA, Jackson HW, Beristain AG, di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465(7299):803–7. https://doi.org/10.1038/nature09091.

CAS  Article  PubMed  Google Scholar 

Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010;465(7299):798–802. https://doi.org/10.1038/nature09027.

CAS  Article  PubMed  Google Scholar 

Poole AJ, Li Y, Kim Y, Lin S-CJ, Lee W-H, Lee EY-HP. Prevention of Brca1-Mediated Mammary Tumorigenesis in Mice by a Progesterone Antagonist. Science (80- ). 2006;314(5804):1467–70. https://doi.org/10.1126/science.1130471.

CAS  Article  Google Scholar 

Nolan E, Vaillant F, Branstetter D, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016;22(8):933–9. https://doi.org/10.1038/nm.4118.

CAS  Article  PubMed  Google Scholar 

Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res. 2016;26(7):761–74. https://doi.org/10.1038/cr.2016.69.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2015;386(9992):433–43. https://doi.org/10.1016/S0140-6736(15)60995-3.

CAS  Article  Google Scholar 

Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(35):5132–9. https://doi.org/10.1200/JCO.2010.29.7101.

CAS  Article  Google Scholar 

Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139–46. https://doi.org/10.1111/ijcp.12022.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Uzelac A. Investigating the role of BRCA1 in the regulation of Osteoprotegerin. Published online. 2020.

Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, et al. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol. 2013;14(12):1226–32. https://doi.org/10.1016/S1470-2045(13)70448-0.

CAS  Article  PubMed  Google Scholar 

Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, et al. Osteoprotegerin (OPG), the endogenous inhibitor of receptor activator of NF-κB ligand (RANKL), is dysregulated in BRCA mutation carriers. EBioMedicine. 2015;2(10):1331–9. https://doi.org/10.1016/j.ebiom.2015.08.037.

Article  PubMed  PubMed Central  Google Scholar 

Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the women’s health initiative observational study. J Natl Cancer Inst. 2013;105(8):526–35. https://doi.org/10.1093/jnci/djt043.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, et al. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018;169(3):561–71. https://doi.org/10.1007/s10549-018-4694-1.

CAS  Article  PubMed  Google Scholar 

Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JAE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s health initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476–86. https://doi.org/10.1016/S1470-2045(12)70075-X.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Group C, Cancer B. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–68. https://doi.org/10.1016/S0140-6736(19)31709-X.

Article  Google Scholar 

Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, et al. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005;16(6):667–74. https://doi.org/10.1007/s10552-005-1724-1.

Article  PubMed  Google Scholar 

Nolan E, Lindeman GJ, Visvader JE. Out-RANKing BRCA1 in mutation carriers. Cancer Res. 2017;77(3):595–600. https://doi.org/10.1158/0008-5472.CAN-16-2025.

CAS  Article  PubMed  Google Scholar 

Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone replacement therapy after oophorectomy and breast Cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059–65. https://doi.org/10.1001/jamaoncol.2018.0211.

Article  PubMed  PubMed Central